

Table 1.14

## Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 17 SEER Areas, 2004-2006

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	40.58	( 40.48, 40.67 )	41.09	( 40.99, 41.20 )	36.49	( 36.20, 36.78 )
Invasive and In Situ	43.37	( 43.27, 43.47 )	43.97	( 43.86, 44.08 )	38.17	( 37.88, 38.47 )
Oral Cavity and Pharynx	1.02	( 1.00, 1.03 )	1.04	( 1.03, 1.06 )	0.83	( 0.79, 0.87 )
Esophagus	0.51	( 0.50, 0.52 )	0.53	( 0.51, 0.54 )	0.47	( 0.44, 0.51 )
Stomach	0.89	( 0.87, 0.90 )	0.78	( 0.76, 0.79 )	1.09	( 1.04, 1.15 )
Colon and Rectum	5.20	( 5.16, 5.23 )	5.18	( 5.14, 5.21 )	5.07	( 4.96, 5.18 )
Invasive and In Situ	5.46	( 5.43, 5.50 )	5.43	( 5.40, 5.47 )	5.37	( 5.26, 5.49 )
Liver and Intrahepatic Bile Duct	0.73	( 0.71, 0.74 )	0.62	( 0.61, 0.63 )	0.75	( 0.71, 0.79 )
Pancreas	1.38	( 1.37, 1.40 )	1.37	( 1.35, 1.39 )	1.49	( 1.43, 1.55 )
Larynx	0.37	( 0.36, 0.37 )	0.37	( 0.36, 0.38 )	0.47	( 0.44, 0.50 )
Invasive and In Situ	0.39	( 0.38, 0.40 )	0.40	( 0.39, 0.41 )	0.49	( 0.46, 0.52 )
Lung and Bronchus	6.96	( 6.92, 7.00 )	7.15	( 7.10, 7.19 )	6.59	( 6.47, 6.71 )
Melanoma of the Skin	1.88	( 1.86, 1.90 )	2.20	( 2.17, 2.22 )	0.08	( 0.07, 0.10 )
Invasive and In Situ	2.99	( 2.96, 3.01 )	3.44	( 3.41, 3.47 )	0.10	( 0.09, 0.12 )
Breast	6.26	( 6.23, 6.30 )	6.46	( 6.42, 6.49 )	5.32	( 5.22, 5.43 )
Invasive and In Situ	7.49	( 7.46, 7.53 )	7.70	( 7.66, 7.74 )	6.41	( 6.30, 6.52 )
Urinary Bladder (Invasive and In Situ)	2.41	( 2.39, 2.43 )	2.61	( 2.58, 2.64 )	1.19	( 1.13, 1.24 )
Kidney and Renal Pelvis	1.43	( 1.42, 1.45 )	1.50	( 1.48, 1.51 )	1.28	( 1.23, 1.33 )
Brain and Other Nervous System	0.60	( 0.59, 0.61 )	0.66	( 0.65, 0.68 )	0.31	( 0.29, 0.34 )
Thyroid	0.84	( 0.83, 0.85 )	0.88	( 0.87, 0.89 )	0.48	( 0.46, 0.51 )
Hodgkin Lymphoma	0.23	( 0.22, 0.24 )	0.25	( 0.24, 0.25 )	0.20	( 0.18, 0.22 )
Non-Hodgkin Lymphoma	2.09	( 2.07, 2.11 )	2.20	( 2.17, 2.22 )	1.25	( 1.20, 1.30 )
Myeloma	0.63	( 0.62, 0.65 )	0.59	( 0.58, 0.60 )	1.08	( 1.03, 1.13 )
Leukemia	1.28	( 1.27, 1.30 )	1.34	( 1.33, 1.36 )	0.84	( 0.80, 0.88 )
Acute Lymphocytic Leukemia	0.12	( 0.12, 0.13 )	0.13	( 0.13, 0.14 )	0.07	( 0.06, 0.08 )
Chronic Lymphocytic Leukemia	0.47	( 0.46, 0.48 )	0.50	( 0.49, 0.51 )	0.27	( 0.25, 0.30 )
Acute Myeloid Leukemia	0.37	( 0.36, 0.38 )	0.38	( 0.37, 0.39 )	0.25	( 0.23, 0.28 )
Chronic Myeloid Leukemia	0.16	( 0.15, 0.16 )	0.16	( 0.15, 0.17 )	0.12	( 0.10, 0.13 )
Kaposi Sarcoma	0.05	( 0.05, 0.05 )	0.05	( 0.04, 0.05 )	0.09	( 0.08, 0.10 )
Mesothelioma	0.13	( 0.12, 0.13 )	0.14	( 0.13, 0.14 )	0.07	( 0.06, 0.08 )

Devcan Version 6.4.0, April 2009, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.14 - continued

## Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 17 SEER Areas, 2004-2006

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	34.97 ( 34.59, 35.37 )	28.06 ( 26.87, 29.38 )	36.64 ( 36.30, 37.00 )
Invasive and In Situ	36.89 ( 36.49, 37.29 )	29.22 ( 28.00, 30.58 )	38.34 ( 37.98, 38.70 )
Oral Cavity and Pharynx	0.87 ( 0.82, 0.93 )	0.64 ( 0.51, 0.99 )	0.69 ( 0.64, 0.74 )
Esophagus	0.39 ( 0.35, 0.44 )	0.51 ( 0.36, 0.87 )	0.38 ( 0.35, 0.42 )
Stomach	1.99 ( 1.89, 2.09 )	1.24 ( 0.96, 1.70 )	1.49 ( 1.42, 1.57 )
Colon and Rectum	5.27 ( 5.11, 5.44 )	4.36 ( 3.88, 4.98 )	4.79 ( 4.65, 4.93 )
Invasive and In Situ	5.49 ( 5.33, 5.66 )	4.56 ( 4.08, 5.19 )	4.99 ( 4.86, 5.14 )
Liver and Intrahepatic Bile Duct	1.84 ( 1.76, 1.94 )	1.04 ( 0.85, 1.43 )	1.26 ( 1.20, 1.33 )
Pancreas	1.48 ( 1.39, 1.58 )	1.13 ( 0.91, 1.55 )	1.48 ( 1.40, 1.56 )
Larynx	0.17 ( 0.14, 0.20 )	0.15 ( 0.09, 0.48 )	0.28 ( 0.26, 0.32 )
Invasive and In Situ	0.18 ( 0.16, 0.22 )	0.16 ( 0.09, 0.49 )	0.30 ( 0.28, 0.34 )
Lung and Bronchus	5.52 ( 5.36, 5.69 )	4.82 ( 4.33, 5.46 )	4.24 ( 4.11, 4.37 )
Melanoma of the Skin	0.16 ( 0.14, 0.20 )	0.33 ( 0.22, 0.67 )	0.52 ( 0.48, 0.57 )
Invasive and In Situ	0.24 ( 0.21, 0.29 )	0.40 ( 0.29, 0.75 )	0.71 ( 0.66, 0.77 )
Breast	5.00 ( 4.88, 5.13 )	3.68 ( 3.31, 4.21 )	4.84 ( 4.73, 4.96 )
Invasive and In Situ	6.19 ( 6.06, 6.33 )	4.24 ( 3.84, 4.79 )	5.72 ( 5.60, 5.85 )
Urinary Bladder(Invasive and In Situ)	1.40 ( 1.31, 1.49 )	0.85 ( 0.67, 1.24 )	1.53 ( 1.46, 1.61 )
Kidney and Renal Pelvis	0.88 ( 0.82, 0.94 )	1.71 ( 1.46, 2.14 )	1.54 ( 1.48, 1.61 )
Brain and Other Nervous System	0.38 ( 0.34, 0.43 )	0.29 ( 0.21, 0.62 )	0.53 ( 0.49, 0.57 )
Thyroid	0.89 ( 0.85, 0.94 )	0.44 ( 0.34, 0.77 )	0.80 ( 0.76, 0.85 )
Hodgkin Lymphoma	0.11 ( 0.10, 0.14 )	0.06 ( 0.04, 0.39 )	0.23 ( 0.21, 0.26 )
Non-Hodgkin Lymphoma	1.69 ( 1.61, 1.79 )	1.20 ( 0.97, 1.62 )	2.03 ( 1.95, 2.12 )
Myeloma	0.47 ( 0.42, 0.52 )	0.47 ( 0.34, 0.82 )	0.66 ( 0.62, 0.71 )
Leukemia	0.88 ( 0.82, 0.95 )	0.84 ( 0.60, 1.27 )	1.10 ( 1.04, 1.17 )
Acute Lymphocytic Leukemia	0.11 ( 0.10, 0.14 )	0.09 ( 0.05, 0.42 )	0.19 ( 0.17, 0.21 )
Chronic Lymphocytic Leukemia	0.16 ( 0.12, 0.20 )	0.27 ( 0.11, 0.70 )	0.28 ( 0.24, 0.32 )
Acute Myeloid Leukemia	0.38 ( 0.34, 0.43 )	0.22 ( 0.14, 0.55 )	0.33 ( 0.30, 0.37 )
Chronic Myeloid Leukemia	0.11 ( 0.09, 0.14 )	0.15 ( 0.08, 0.48 )	0.16 ( 0.13, 0.19 )
Kaposi Sarcoma	0.02 ( 0.01, 0.05 )	0.04 ( 0.01, 0.39 )	0.09 ( 0.08, 0.12 )
Mesothelioma	0.05 ( 0.04, 0.07 )	0.10 ( 0.04, 0.44 )	0.13 ( 0.11, 0.16 )

Devcan Version 6.4.0, April 2009, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.15

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Males, 17 SEER Areas, 2004-2006

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	44.05	( 43.91, 44.20 )	44.16	( 44.00, 44.33 )	40.50	( 40.05, 40.95 )
Invasive and In Situ	45.93	( 45.78, 46.08 )	46.13	( 45.96, 46.29 )	41.15	( 40.70, 41.61 )
Oral Cavity and Pharynx	1.40	( 1.37, 1.42 )	1.43	( 1.41, 1.46 )	1.18	( 1.11, 1.25 )
Esophagus	0.79	( 0.77, 0.81 )	0.82	( 0.80, 0.84 )	0.68	( 0.63, 0.75 )
Stomach	1.11	( 1.09, 1.14 )	0.99	( 0.97, 1.01 )	1.27	( 1.20, 1.36 )
Colon and Rectum	5.39	( 5.34, 5.44 )	5.40	( 5.34, 5.45 )	4.97	( 4.81, 5.13 )
Invasive and In Situ	5.69	( 5.64, 5.74 )	5.70	( 5.64, 5.75 )	5.28	( 5.12, 5.44 )
Liver and Intrahepatic Bile Duct	1.01	( 0.99, 1.03 )	0.87	( 0.85, 0.89 )	1.08	( 1.01, 1.15 )
Pancreas	1.38	( 1.35, 1.40 )	1.38	( 1.35, 1.41 )	1.33	( 1.25, 1.41 )
Larynx	0.61	( 0.59, 0.63 )	0.62	( 0.60, 0.63 )	0.79	( 0.74, 0.86 )
Invasive and In Situ	0.66	( 0.64, 0.67 )	0.67	( 0.65, 0.68 )	0.83	( 0.77, 0.89 )
Lung and Bronchus	7.73	( 7.67, 7.79 )	7.81	( 7.75, 7.88 )	7.74	( 7.55, 7.94 )
Melanoma of the Skin	2.30	( 2.27, 2.33 )	2.67	( 2.63, 2.71 )	0.08	( 0.06, 0.11 )
Invasive and In Situ	3.63	( 3.59, 3.67 )	4.16	( 4.12, 4.21 )	0.11	( 0.09, 0.14 )
Breast	0.12	( 0.11, 0.13 )	0.12	( 0.12, 0.13 )	0.12	( 0.10, 0.15 )
Invasive and In Situ	0.13	( 0.12, 0.14 )	0.14	( 0.13, 0.14 )	0.14	( 0.11, 0.17 )
Prostate	15.90	( 15.81, 15.98 )	15.39	( 15.30, 15.48 )	18.32	( 18.03, 18.62 )
Testis	0.37	( 0.36, 0.38 )	0.44	( 0.43, 0.45 )	0.08	( 0.07, 0.10 )
Urinary Bladder(Invasive and In Situ)	3.81	( 3.76, 3.85 )	4.14	( 4.09, 4.19 )	1.56	( 1.47, 1.65 )
Kidney and Renal Pelvis	1.80	( 1.78, 1.83 )	1.88	( 1.85, 1.91 )	1.58	( 1.50, 1.67 )
Brain and Other Nervous System	0.67	( 0.66, 0.69 )	0.74	( 0.72, 0.76 )	0.33	( 0.29, 0.37 )
Thyroid	0.44	( 0.43, 0.45 )	0.47	( 0.45, 0.48 )	0.22	( 0.20, 0.26 )
Hodgkin Lymphoma	0.25	( 0.24, 0.25 )	0.26	( 0.25, 0.27 )	0.21	( 0.19, 0.24 )
Non-Hodgkin Lymphoma	2.28	( 2.24, 2.31 )	2.39	( 2.35, 2.42 )	1.34	( 1.27, 1.42 )
Myeloma	0.72	( 0.70, 0.74 )	0.68	( 0.66, 0.70 )	1.09	( 1.02, 1.17 )
Leukemia	1.51	( 1.48, 1.53 )	1.59	( 1.56, 1.62 )	0.94	( 0.87, 1.01 )
Acute Lymphocytic Leukemia	0.14	( 0.13, 0.14 )	0.15	( 0.14, 0.16 )	0.07	( 0.06, 0.10 )
Chronic Lymphocytic Leukemia	0.58	( 0.56, 0.60 )	0.62	( 0.60, 0.64 )	0.34	( 0.30, 0.39 )
Acute Myeloid Leukemia	0.42	( 0.40, 0.43 )	0.44	( 0.42, 0.45 )	0.25	( 0.22, 0.29 )
Chronic Myeloid Leukemia	0.18	( 0.17, 0.19 )	0.19	( 0.18, 0.20 )	0.14	( 0.11, 0.17 )
Kaposi Sarcoma	0.09	( 0.08, 0.09 )	0.08	( 0.07, 0.09 )	0.16	( 0.14, 0.19 )
Mesothelioma	0.21	( 0.20, 0.22 )	0.23	( 0.22, 0.24 )	0.11	( 0.09, 0.14 )

Devcan Version 6.4.0, April 2009, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.15 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Males, 17 SEER Areas, 2004-2006

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	38.15 ( 37.56, 38.75 )	27.02 ( 25.35, 29.09 )	40.58 ( 40.02, 41.15 )
Invasive and In Situ	39.12 ( 38.52, 39.73 )	27.97 ( 26.19, 30.14 )	41.46 ( 40.90, 42.04 )
Oral Cavity and Pharynx	1.08 ( 1.01, 1.18 )	0.64 ( 0.47, 1.51 )	0.96 ( 0.88, 1.07 )
Esophagus	0.57 ( 0.50, 0.66 )	0.58 ( 0.38, 1.48 )	0.62 ( 0.56, 0.70 )
Stomach	2.43 ( 2.28, 2.59 )	1.67 ( 1.10, 2.82 )	1.74 ( 1.62, 1.87 )
Colon and Rectum	5.54 ( 5.31, 5.79 )	3.73 ( 3.17, 4.79 )	5.21 ( 5.01, 5.44 )
Invasive and In Situ	5.79 ( 5.56, 6.04 )	3.93 ( 3.36, 5.00 )	5.46 ( 5.25, 5.70 )
Liver and Intrahepatic Bile Duct	2.44 ( 2.31, 2.58 )	1.23 ( 0.95, 2.12 )	1.67 ( 1.58, 1.78 )
Pancreas	1.49 ( 1.36, 1.63 )	1.01 ( 0.70, 1.95 )	1.34 ( 1.25, 1.46 )
Larynx	0.31 ( 0.26, 0.38 )	0.18 ( 0.08, 1.08 )	0.52 ( 0.47, 0.59 )
Invasive and In Situ	0.34 ( 0.29, 0.42 )	0.19 ( 0.09, 1.09 )	0.55 ( 0.50, 0.63 )
Lung and Bronchus	6.92 ( 6.67, 7.18 )	4.99 ( 4.19, 6.28 )	5.17 ( 4.96, 5.41 )
Melanoma of the Skin	0.17 ( 0.14, 0.23 )	0.35 ( 0.19, 1.25 )	0.55 ( 0.48, 0.66 )
Invasive and In Situ	0.23 ( 0.19, 0.30 )	0.44 ( 0.26, 1.34 )	0.76 ( 0.68, 0.87 )
Breast	0.06 ( 0.04, 0.11 )	0.01 ( 0.00, 0.96 )	0.08 ( 0.06, 0.13 )
Invasive and In Situ	0.07 ( 0.05, 0.12 )	0.01 ( 0.00, 0.96 )	0.08 ( 0.06, 0.14 )
Prostate	11.68 ( 11.36, 12.01 )	7.45 ( 6.58, 8.76 )	15.06 ( 14.76, 15.39 )
Testis	0.14 ( 0.12, 0.18 )	0.26 ( 0.19, 1.14 )	0.29 ( 0.27, 0.34 )
Urinary Bladder(Invasive and In Situ)	2.24 ( 2.09, 2.40 )	1.26 ( 0.95, 2.18 )	2.43 ( 2.29, 2.59 )
Kidney and Renal Pelvis	1.12 ( 1.03, 1.23 )	1.86 ( 1.50, 2.81 )	1.94 ( 1.83, 2.07 )
Brain and Other Nervous System	0.41 ( 0.35, 0.49 )	0.27 ( 0.16, 1.16 )	0.60 ( 0.55, 0.68 )
Thyroid	0.43 ( 0.38, 0.51 )	0.27 ( 0.14, 1.17 )	0.37 ( 0.32, 0.44 )
Hodgkin Lymphoma	0.13 ( 0.10, 0.17 )	0.08 ( 0.04, 1.00 )	0.24 ( 0.22, 0.30 )
Non-Hodgkin Lymphoma	1.96 ( 1.82, 2.11 )	1.17 ( 0.85, 2.10 )	2.10 ( 1.98, 2.25 )
Myeloma	0.53 ( 0.47, 0.62 )	0.50 ( 0.31, 1.40 )	0.71 ( 0.64, 0.80 )
Leukemia	1.00 ( 0.91, 1.11 )	0.83 ( 0.60, 1.73 )	1.27 ( 1.16, 1.39 )
Acute Lymphocytic Leukemia	0.13 ( 0.11, 0.18 )	0.10 ( 0.04, 1.02 )	0.19 ( 0.17, 0.24 )
Chronic Lymphocytic Leukemia	0.18 ( 0.13, 0.25 )	0.26 ( 0.13, 1.16 )	0.32 ( 0.26, 0.41 )
Acute Myeloid Leukemia	0.41 ( 0.36, 0.49 )	0.18 ( 0.08, 1.09 )	0.38 ( 0.34, 0.45 )
Chronic Myeloid Leukemia	0.14 ( 0.11, 0.19 )	0.17 ( 0.06, 1.08 )	0.20 ( 0.15, 0.28 )
Kaposi Sarcoma	0.04 ( 0.03, 0.08 )	0.05 ( 0.02, 0.98 )	0.16 ( 0.13, 0.22 )
Mesothelioma	0.09 ( 0.06, 0.14 )	0.13 ( 0.05, 1.05 )	0.21 ( 0.17, 0.27 )

Devcan Version 6.4.0, April 2009, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 17 SEER Areas, 2004-2006

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	37.63	( 37.51, 37.75 )	38.52	( 38.38, 38.66 )	32.92	( 32.55, 33.30 )
Invasive and In Situ	41.34	( 41.21, 41.47 )	42.33	( 42.19, 42.48 )	35.56	( 35.17, 35.95 )
Oral Cavity and Pharynx	0.66	( 0.65, 0.68 )	0.67	( 0.65, 0.68 )	0.51	( 0.47, 0.56 )
Esophagus	0.25	( 0.24, 0.26 )	0.25	( 0.24, 0.26 )	0.28	( 0.25, 0.32 )
Stomach	0.68	( 0.67, 0.70 )	0.58	( 0.57, 0.60 )	0.93	( 0.87, 1.00 )
Colon and Rectum	5.03	( 4.99, 5.08 )	4.98	( 4.93, 5.03 )	5.18	( 5.03, 5.33 )
Invasive and In Situ	5.27	( 5.22, 5.31 )	5.20	( 5.15, 5.25 )	5.48	( 5.33, 5.64 )
Liver and Intrahepatic Bile Duct	0.46	( 0.44, 0.47 )	0.38	( 0.37, 0.40 )	0.44	( 0.40, 0.49 )
Pancreas	1.39	( 1.37, 1.42 )	1.36	( 1.34, 1.39 )	1.63	( 1.55, 1.72 )
Larynx	0.14	( 0.13, 0.15 )	0.15	( 0.14, 0.16 )	0.18	( 0.15, 0.21 )
Invasive and In Situ	0.15	( 0.14, 0.16 )	0.16	( 0.15, 0.17 )	0.19	( 0.16, 0.22 )
Lung and Bronchus	6.31	( 6.25, 6.36 )	6.60	( 6.54, 6.66 )	5.57	( 5.42, 5.73 )
Melanoma of the Skin	1.52	( 1.50, 1.55 )	1.79	( 1.76, 1.82 )	0.09	( 0.07, 0.11 )
Invasive and In Situ	2.44	( 2.41, 2.47 )	2.82	( 2.79, 2.86 )	0.10	( 0.08, 0.13 )
Breast	12.08	( 12.01, 12.15 )	12.54	( 12.46, 12.61 )	10.07	( 9.88, 10.27 )
Invasive and In Situ	14.49	( 14.41, 14.56 )	14.99	( 14.91, 15.07 )	12.14	( 11.93, 12.35 )
Cervix Uteri	0.69	( 0.67, 0.70 )	0.67	( 0.65, 0.68 )	0.82	( 0.77, 0.88 )
Corpus and Uterus, NOS	2.53	( 2.50, 2.56 )	2.65	( 2.62, 2.69 )	1.97	( 1.88, 2.06 )
Invasive and In Situ	2.56	( 2.52, 2.59 )	2.68	( 2.65, 2.72 )	2.00	( 1.91, 2.09 )
Ovary <sup>a</sup>	1.40	( 1.38, 1.42 )	1.48	( 1.46, 1.51 )	0.93	( 0.88, 1.00 )
Urinary Bladder(Invasive and In Situ)	1.18	( 1.16, 1.21 )	1.26	( 1.23, 1.28 )	0.86	( 0.80, 0.93 )
Kidney and Renal Pelvis	1.09	( 1.07, 1.11 )	1.14	( 1.11, 1.16 )	1.00	( 0.94, 1.07 )
Brain and Other Nervous System	0.54	( 0.53, 0.55 )	0.59	( 0.57, 0.61 )	0.30	( 0.27, 0.34 )
Thyroid	1.25	( 1.23, 1.27 )	1.31	( 1.29, 1.33 )	0.73	( 0.68, 0.78 )
Hodgkin Lymphoma	0.21	( 0.21, 0.22 )	0.23	( 0.22, 0.24 )	0.19	( 0.17, 0.21 )
Non-Hodgkin Lymphoma	1.92	( 1.89, 1.95 )	2.02	( 1.99, 2.06 )	1.17	( 1.10, 1.24 )
Myeloma	0.56	( 0.55, 0.58 )	0.51	( 0.49, 0.52 )	1.08	( 1.01, 1.15 )
Leukemia	1.08	( 1.06, 1.10 )	1.13	( 1.10, 1.15 )	0.76	( 0.70, 0.82 )
Acute Lymphocytic Leukemia	0.11	( 0.10, 0.11 )	0.12	( 0.11, 0.12 )	0.07	( 0.05, 0.09 )
Chronic Lymphocytic Leukemia	0.38	( 0.37, 0.39 )	0.40	( 0.39, 0.42 )	0.22	( 0.19, 0.26 )
Acute Myeloid Leukemia	0.33	( 0.32, 0.34 )	0.33	( 0.32, 0.35 )	0.26	( 0.23, 0.29 )
Chronic Myeloid Leukemia	0.13	( 0.12, 0.14 )	0.14	( 0.13, 0.14 )	0.10	( 0.08, 0.12 )
Kaposi Sarcoma	0.01	( 0.01, 0.02 )	0.01	( 0.01, 0.01 )	0.02	( 0.01, 0.03 )
Mesothelioma	0.05	( 0.05, 0.06 )	0.06	( 0.05, 0.06 )	0.03	( 0.02, 0.05 )

Devcan Version 6.4.0, April 2009, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16 - continued

## Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 17 SEER Areas, 2004-2006

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	32.43 ( 31.92, 32.97 )	29.15 ( 27.48, 31.07 )	33.64 ( 33.19, 34.11 )
Invasive and In Situ	35.19 ( 34.66, 35.74 )	30.60 ( 28.90, 32.56 )	36.12 ( 35.65, 36.60 )
Oral Cavity and Pharynx	0.68 ( 0.61, 0.78 )	0.64 ( 0.44, 1.23 )	0.44 ( 0.39, 0.51 )
Esophagus	0.23 ( 0.18, 0.31 )	0.42 ( 0.24, 1.02 )	0.17 ( 0.14, 0.22 )
Stomach	1.62 ( 1.48, 1.77 )	0.89 ( 0.62, 1.52 )	1.29 ( 1.19, 1.40 )
Colon and Rectum	5.03 ( 4.82, 5.27 )	4.90 ( 4.19, 5.90 )	4.43 ( 4.25, 4.62 )
Invasive and In Situ	5.23 ( 5.01, 5.46 )	5.10 ( 4.38, 6.11 )	4.60 ( 4.42, 4.80 )
Liver and Intrahepatic Bile Duct	1.33 ( 1.21, 1.47 )	0.86 ( 0.61, 1.48 )	0.87 ( 0.80, 0.96 )
Pancreas	1.48 ( 1.35, 1.63 )	1.26 ( 0.93, 1.93 )	1.58 ( 1.47, 1.71 )
Larynx	0.04 ( 0.03, 0.09 )	0.12 ( 0.05, 0.70 )	0.08 ( 0.06, 0.11 )
Invasive and In Situ	0.05 ( 0.03, 0.10 )	0.12 ( 0.05, 0.70 )	0.08 ( 0.07, 0.12 )
Lung and Bronchus	4.34 ( 4.14, 4.56 )	4.73 ( 4.10, 5.64 )	3.49 ( 3.34, 3.65 )
Melanoma of the Skin	0.16 ( 0.13, 0.21 )	0.32 ( 0.19, 0.89 )	0.51 ( 0.46, 0.58 )
Invasive and In Situ	0.25 ( 0.20, 0.33 )	0.38 ( 0.23, 0.95 )	0.70 ( 0.64, 0.77 )
Breast	9.36 ( 9.13, 9.60 )	7.21 ( 6.50, 8.19 )	9.29 ( 9.08, 9.50 )
Invasive and In Situ	11.59 ( 11.34, 11.85 )	8.30 ( 7.53, 9.32 )	11.00 ( 10.78, 11.23 )
Cervix Uteri	0.76 ( 0.70, 0.85 )	0.66 ( 0.47, 1.25 )	1.16 ( 1.10, 1.24 )
Corpus and Uterus, NOS	1.87 ( 1.76, 1.98 )	1.77 ( 1.33, 2.53 )	2.03 ( 1.94, 2.14 )
Invasive and In Situ	1.88 ( 1.78, 2.00 )	1.78 ( 1.35, 2.55 )	2.05 ( 1.96, 2.16 )
Ovary <sup>c</sup>	1.11 ( 1.03, 1.21 )	1.20 ( 0.91, 1.83 )	1.33 ( 1.25, 1.43 )
Urinary Bladder(Invasive and In Situ)	0.67 ( 0.60, 0.77 )	0.47 ( 0.28, 1.06 )	0.77 ( 0.70, 0.85 )
Kidney and Renal Pelvis	0.66 ( 0.59, 0.76 )	1.56 ( 1.24, 2.22 )	1.20 ( 1.12, 1.29 )
Brain and Other Nervous System	0.36 ( 0.31, 0.44 )	0.31 ( 0.19, 0.87 )	0.46 ( 0.42, 0.52 )
Thyroid	1.31 ( 1.24, 1.40 )	0.61 ( 0.46, 1.17 )	1.24 ( 1.18, 1.32 )
Hodgkin Lymphoma	0.10 ( 0.08, 0.15 )	0.05 ( 0.02, 0.63 )	0.21 ( 0.18, 0.26 )
Non-Hodgkin Lymphoma	1.47 ( 1.35, 1.60 )	1.24 ( 0.92, 1.91 )	1.98 ( 1.86, 2.10 )
Myeloma	0.41 ( 0.35, 0.49 )	0.45 ( 0.28, 1.03 )	0.62 ( 0.56, 0.69 )
Leukemia	0.78 ( 0.69, 0.88 )	0.81 ( 0.47, 1.54 )	0.96 ( 0.89, 1.05 )
Acute Lymphocytic Leukemia	0.10 ( 0.08, 0.15 )	0.08 ( 0.04, 0.65 )	0.19 ( 0.17, 0.22 )
Chronic Lymphocytic Leukemia	0.14 ( 0.09, 0.21 )	0.26 ( 0.04, 0.99 )	0.25 ( 0.20, 0.30 )
Acute Myeloid Leukemia	0.35 ( 0.30, 0.42 )	0.25 ( 0.14, 0.82 )	0.28 ( 0.25, 0.34 )
Chronic Myeloid Leukemia	0.08 ( 0.06, 0.13 )	0.13 ( 0.05, 0.70 )	0.12 ( 0.10, 0.16 )
Kaposi Sarcoma	0.01 ( 0.00, 0.05 )	0.04 ( 0.00, 0.63 )	0.03 ( 0.01, 0.06 )
Mesothelioma	0.01 ( 0.01, 0.06 )	0.07 ( 0.01, 0.65 )	0.07 ( 0.05, 0.11 )

Devcan Version 6.4.0, April 2009, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>c</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.